Growth Hormone Disorders Completed Phase 1 Trials for Somatotropin (DB00052)

Also known as: Growth Hormone Disorder

IndicationStatusPhase
DBCOND0036845 (Growth Hormone Disorders)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01973244A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone DeficiencyTreatment
NCT01706783A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone DeficiencyTreatment
NCT01034202Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®Treatment
NCT00931476A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of SomatropinTreatment